menu
    • menu
    [{"orgOrder":0,"company":"Baker Institute","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Milrinone","moa":"PDE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Baker Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Baker Institute \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Baker Institute \/ Hyloris Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for Milrinone

    Menu

    Milrinone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Baker Institute

                            Country arrow
                            Fi Europe 2024
                            Not Confirmed

                            Baker Institute

                            Country arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Milrinone

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Hyloris Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Hyloris Expands Cardiovascular Pipeline with Breakthrough Extended-Release Milrinone Capsule in Late-Stage Hea...

                            Details : Under the terms of the agreement, Hyloris will be responsible for the development, manufacturing, regulatory affairs, and commercialisation of CRD-102. CRD-102 is a novel, patented, extended-release Milrinone capsule.

                            Brand Name : CRD-102

                            Molecule Type : Small molecule

                            Upfront Cash : $0.1 million

                            October 08, 2021

                            Lead Product(s) : Milrinone

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Hyloris Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth